1. Home
  2. TY vs PVLA Comparison

TY vs PVLA Comparison

Compare TY & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tri Continental Corporation

TY

Tri Continental Corporation

HOLD

Current Price

$35.64

Market Cap

1.9B

Sector

Finance

ML Signal

HOLD

Logo Palvella Therapeutics Inc.

PVLA

Palvella Therapeutics Inc.

HOLD

Current Price

$158.71

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TY
PVLA
Founded
1929
2015
Country
United States
United States
Employees
N/A
29
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
2.0B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TY
PVLA
Price
$35.64
$158.71
Analyst Decision
Strong Buy
Analyst Count
0
15
Target Price
N/A
$171.87
AVG Volume (30 Days)
24.7K
182.8K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
3.36%
N/A
EPS Growth
N/A
N/A
EPS
4.78
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$104,350.18
P/E Ratio
$7.47
N/A
Revenue Growth
N/A
N/A
52 Week Low
$30.53
$40.92
52 Week High
$36.05
$161.38

Technical Indicators

Market Signals
Indicator
TY
PVLA
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
TY
PVLA

About TY Tri Continental Corporation

Tri-Continental Corp is a closed-end management investment company. It invests to produce future growth of both capital and income while providing reasonable current income. The fund is divided into two equal segments namely, the equity segment uses quantitative models to select individual stocks whereas the Flexible capital income segment invests across a company's investable capital structure, including stocks, bonds, and convertible securities. The Fund invests in a range of sectors, which include consumer discretionary, consumer staples, energy, financials, healthcare, industrials, information technology, industrials, materials, real estate, telecommunication services, utilities, aerospace and defense, banking, chemicals, and others.

About PVLA Palvella Therapeutics Inc.

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.

Share on Social Networks: